Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 0378-9071; 51956-0001; 51956-0003; 70710-1198; 65162-826; 49706-1825; 51956-0002; 0078-0502; 72855-100; 0378-9070; 50379-0014; 65015-819; 46708-835; 51991-899; 0078-0503; 63629-8846; 65862-982; 65162-825; 72855-101; 63629-8807; 63629-2065; 65162-749; 51991-898; 0378-9072; 64552-4021; 0781-7313; 72855-102; 16714-117; 16714-116; 51991-897; 0781-7309; 70710-1196; 12651-118; 63629-2066; 0078-0501; 16714-115; 0781-7304; 65372-1153; 82245-0107; 63629-2064; 70710-1197
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DiarrhoeaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DizzinessCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
VomitingCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.004968%Not Available
Malaise08.01.01.003--
Mania19.16.02.0020.002484%
Memory impairment19.20.01.003; 17.03.02.0030.006210%
Mental impairment19.21.02.003; 17.03.03.0020.002484%Not Available
Miosis17.02.11.002; 06.05.03.0030.003726%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.004968%Not Available
Nausea07.01.07.0010.017388%
Nightmare19.02.03.0030.002484%Not Available
Nocturia20.02.03.0010.003726%Not Available
Oesophageal carcinoma16.13.06.001; 07.21.06.0010.000648%Not Available
Oesophagitis07.08.05.0010.000648%
On and off phenomenon17.01.05.0040.004968%Not Available
Pleurothotonus17.01.03.0090.002484%Not Available
Pneumonia22.07.01.003; 11.01.09.0030.009936%Not Available
Pruritus23.03.12.0010.006210%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.003726%Not Available
Pyrexia08.05.02.0030.003726%
Rash23.03.13.0010.009936%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000972%
Restlessness19.11.02.002; 17.02.05.021--
Rib fracture12.04.07.001; 15.08.07.0010.002484%Not Available
Salivary hypersecretion07.06.01.0090.004968%Not Available
Seizure17.12.03.0010.003726%
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.001296%Not Available
Sinus bradycardia02.03.03.0090.003726%
Skin exfoliation23.03.07.0030.002484%Not Available
Skin irritation23.03.04.0090.004968%Not Available
Skin reaction10.01.03.019; 23.03.03.0130.002484%Not Available
Somnolence19.02.05.003; 17.02.04.0060.004968%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages